MedTrace Logo

Prostate Cancer Biobank

NCT04024475 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1323

Last updated 2022-06-08

No results posted yet for this study

Summary

Carcinoma of the prostate is the second most commonly diagnosed cancer and occurs predominantly in older men - almost two-thirds of those affected are over 65 years of age. In a significant proportion of patients, the disease is harmless and progresses only very slowly. As a result, there is a risk of overdiagnosis and overtreatment. The main diagnostic tool for prostate cancer is the prostate-specific antigen (PSA) test, but its specificity is minimal. It is important to look for other biological characteristics (biomarkers) that provide pointers to the need for a diagnosis and treatment. Even after treatment and in advanced stages of disease, decisions are often difficult, because it is not necessarily clear which patient needs a specific treatment.

In this study, a multicenter biobank of patient sera, plasma and tissue is being established together with information of relevance to the disease, in order to provide a basis for the testing of biomarkers. The aim is to identify markers that offer diagnostic and treatment-selective pointers and thus make a decisive contribution to the optimum care of patients.

Conditions

  • Prostatic Neoplasms

Interventions

OTHER

Observation

Sponsors & Collaborators

  • ProteoMediX AG

    collaborator INDUSTRY

  • Cantonal Hospital of St. Gallen

    collaborator OTHER

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Daniel Engeler, MD · Cantonal Hospital of St. Gallen

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-04
Primary Completion
2022-12-31
Completion
2029-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04024475 on ClinicalTrials.gov